SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs rally to fresh highs is drawing attention alongside Goldman Sachs Buy upgrade, which points to growth opportunities in sovereign AI and customized software. Bulls are celebrating the breakout and possible short-covering, while skeptics argue the valuation is stretched and warn of a pullback.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumbles shift into AI cloud infrastructure, centered on a reported multi-year Anthropic compute agreement and the Maysville data-center buildout, is driving attention. Bulls see major growth potential and point to heavy short interest, while skeptics focus on financing, execution, and the lack of clear updates as the shares have struggled.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflakes Agentic Marketplace Discovery launch and an analyst price-target increase are drawing attention, with traders viewing the move as another sign of AI-driven opportunity and pointing to the stocks sharp rise. Bullish breakout talk is balanced by concerns about its high valuation and lack of GAAP profitability.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Speculation that investor Opaleye is unwinding or trimming its HROW position is driving concern about continued selling pressure; traders disagree on whether it is a full exit or a partial sale. The discussion also looks ahead to Q3 revenue and reflects skepticism about management execution after past guidance disappointments.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Nasdaq-100 reentry and a reported NIH effort to accelerate cancer-vaccine development are driving attention, alongside optimism about its Phase 3 personalized melanoma-vaccine results with Merck. Bulls point to index-fund buying and oncology potential, while skeptics argue the rally has outpaced the companys fundamentals and that the vaccine is not yet an approved commercial product.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

SpaceXs agreement to acquire low-band spectrum has intensified concerns that it could compete with AST SpaceMobile, contributing to a sharp selloff. Traders disagree on whether the deal threatens ASTS or could strengthen its role as a carrier-aligned satellite partner; the CEO has argued that existing carrier spectrum access remains a strategic advantage, while skeptics cite execution and deployment risks.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp pullback despite strong growth and earnings is driving debate, with traders blaming insider selling and macro concerns while bullish investors argue the business remains undervalued and look for a rebound. The discussion also focuses on whether recent weakness is a buying opportunity or a sign the stock could fall further.

Ethena is a delta-hedged synthetic dollar with native crypto yield derived from staking and perpetual funding rate

Ethena USDe

Discussion centers on expanding Ethena USDe adoption through exchange, payments, and DeFi integrations, with traders also focusing on whether USDe growth could support ENA through fee revenue and buybacks. USDe is expected to remain near its dollar peg, so the bullish debate is mainly about ecosystem growth and ENAs indirect value accrual rather than USDe price appreciation.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs persistent weakness despite Bitcoin and broader-market resilience is driving discussion, with traders questioning why the miner is not participating in crypto rebounds. Bearish posts cite short pressure, management, and uncertainty around its AI/data-center pivot and prospective tenant deals, while some see the selloff as a buying opportunity ahead of a Bitcoin recovery or contract news.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solanas recent weakness amid a broader crypto-market pullback is driving discussion, with traders noting its underperformance and watching for technical support. The community is split between warnings of further downside and holders treating the dip as a buying and staking opportunity; some also point to Solanas institutional and tokenization use cases as longer-term positives.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -104.76% and +5.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Earnings Expected to Grow: Should You Buy?

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy

Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme

Equity

Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance. 


Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal Medicare copay scheme. Here's what you should know.read more...

Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?

Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Noteworthy Friday Option Activity: TARS, LYV, RIOT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tarsus Pharmaceuticals Inc (Symbol: TARS), where a total volume of 3,560 contracts has been traded thus far today, a contract volume which is representative of a...

Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Tarsus Pharmaceuticals Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$TARS quietly put up over $600M in sales, growing near 160% a year for three straight years. Now the 50-day just crossed above the 200-day, a golden cross on the daily. Real growth plus a real chart.

Look what we see on our side with our company deep dive tools

MadStockAlerts

$TARS demodex isn't unique to the USA, wait until the global revenue  starts coming in.  Meibomian gland dysfunction treatment approval also just starting to gain momentum #xdemvy

$TARS Tarsus Pharmaceuticals resumed with a Buy at Goldman Sachs 
 
Goldman Sachs analyst Andrea Newkirk resumed coverage of Tarsus Pharmaceuticals with a Buy rating and $116 price target. Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite a backdrop of elevated macro volatility and rising interest rates. The rally has been supported by robust acquisition activity, positive clinical catalysts, and a more constructive regulatory outlook, the analyst tells investors in a research note. Goldman favors companies with "de-risked commercial execution and underappreciated pipeline optionality."

DonCorleone77

$TARS This breakout got ugly quick. Down about 9% from the buy point and now trying to find its footing again.

Not exactly earning more ice time right now.

Breakouts _ Chirps _ Winners

$TARS I’m hoping this pulls back to the low 70s so I can reload. Got lucky and dumped my shares between 89 and 91.

$TARS added another 500 today. Sell the rips and buy the dips is the only way to play this one.￼

Feed

News

Sentiment

Earnings

Fundamentals

Info

TARS Tarsus Pharmaceuticals Inc

Fundamentals

Latest TARS News